NCT07140640 Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery
| NCT ID | NCT07140640 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Aswan University |
| Condition | Cesarean Section Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 666 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 666 participants in total. It began in 2025-09-15 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.
Eligibility Criteria
Inclusion Criteria: * • Pregnant women aged 18-45 years. * ASA physical status II-III. Exclusion Criteria: * • Twin pregnancies. * Contraindications to spinal anesthesia (e.g., coagulopathy, infection). * Patients with incomplete preoperative data for risk stratification.
Contact & Investigator
Ayman Mohamdy Eldemerdash, consultant
STUDY DIRECTOR
Aswan University
Frequently Asked Questions
Who can join the NCT07140640 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Cesarean Section Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07140640 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07140640 currently recruiting?
Yes, NCT07140640 is actively recruiting participants. Contact the research team at emanmahmoud37@gmail.com for enrollment information.
Where is the NCT07140640 trial being conducted?
This trial is being conducted at Aswān, Egypt.
Who is sponsoring the NCT07140640 clinical trial?
NCT07140640 is sponsored by Aswan University. The principal investigator is Ayman Mohamdy Eldemerdash, consultant at Aswan University. The trial plans to enroll 666 participants.